Eterna Therapeutics Inc
NASDAQ:ERNA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Eterna Therapeutics Inc
NASDAQ:ERNA
|
US |
|
L
|
Luzerner Kantonalbank AG
F:4J6
|
CH |
|
Community Bank System Inc
NYSE:CBU
|
US |
Eterna Therapeutics Inc
Eterna Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Brooklyn, New York and currently employs 10 full-time employees. Eterna Therapeutics Inc., formerly Brooklyn ImmunoTherapeutics Inc., is a clinical-stage biopharmaceutical company. The firm is focused on developing cytokine-based therapies for treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Its lead product candidate, IRX-2, is a cytokine therapy, to treat patients with head and neck cancer. IRX-2 is a mixed, human-derived cytokine product with multiple active constituents including Interleukin-2 (IL2) and other key cytokines, which restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. The firm also has multiple cell and gene-editing therapies in preclinical development for various indications, including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. Its subsidiaries include Brooklyn ImmunoTherapeutics LLC, Novellus, Inc. and Novellus Therapeutics, Ltd.
Eterna Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Brooklyn, New York and currently employs 10 full-time employees. Eterna Therapeutics Inc., formerly Brooklyn ImmunoTherapeutics Inc., is a clinical-stage biopharmaceutical company. The firm is focused on developing cytokine-based therapies for treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Its lead product candidate, IRX-2, is a cytokine therapy, to treat patients with head and neck cancer. IRX-2 is a mixed, human-derived cytokine product with multiple active constituents including Interleukin-2 (IL2) and other key cytokines, which restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. The firm also has multiple cell and gene-editing therapies in preclinical development for various indications, including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. Its subsidiaries include Brooklyn ImmunoTherapeutics LLC, Novellus, Inc. and Novellus Therapeutics, Ltd.
